SARS-CoV-2 Spike RBD Beta Variant

Product Description

SARS-CoV-2 Spike RBD Beta Variant
Catalog number: B2010499
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 27 kDa
Supplied as: Lyophilized Powder
Applications: molecular component of many serological and antigenic assays for SARS-CoV-2 and its variants
Storage: -20℃
Keywords: Beta Variant Spike, B.1.351 Spike RBD, Beta RBD
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Rattanapisit K, Bulaon CJI, Khorattanakulchai N, Shanmugaraj B, Wangkanont K,
Phoolcharoen W. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants
showed differential binding efficiency with anti-spike specific monoclonal
antibodies. PLoS One. 2021 Aug 11;16(8):e0253574.

2: Kim S, Liu Y, Lei Z, Dicker J, Cao Y, Zhang XF, Im W. Differential
Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
bioRxiv [Preprint]. 2021 Jul 26:2021.07.23.453598.

3: Peters MH, Bastidas O, Kokron DS, Henze CE. Transformations, Lineage
Comparisons, and Analysis of Down to Up Protomer States of Variants of the SARS-
CoV-2 Prefusion Spike Protein Including the UK Variant B.1.1.7. bioRxiv
[Preprint]. 2021 Apr 2:2021.02.09.430519.

4: Trigueiro-Louro J, Correia V, Figueiredo-Nunes I, Gíria M, Rebelo-de-Andrade
H. Unlocking COVID therapeutic targets: A structure-based rationale against
SARS-CoV-2, SARS-CoV and MERS-CoV Spike. Comput Struct Biotechnol J. 2020 Jul
31;18:2117-2131.

5: Jawad B, Adhikari P, Podgornik R, Ching WY. Key Interacting Residues between
RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics
Simulation and Density Functional Calculation. J Chem Inf Model. 2021 Aug
24:acs.jcim.1c00560.

6: Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, Meyer
B, Rudich Y, Li C, Marton I, Dym O, Elad N, Lewis MG, Andersen H, Gagne M, Seder
RA, Douek DC, Schreiber G. SARS-CoV-2 variant prediction and antiviral drug
design are enabled by RBD in vitro evolution. Nat Microbiol. 2021
Sep;6(9):1188-1198.

7: Ou J, Zhou Z, Dai R, Zhang J, Zhao S, Wu X, Lan W, Ren Y, Cui L, Lan Q, Lu L,
Seto D, Chodosh J, Wu J, Zhang G, Zhang Q. V367F Mutation in SARS-CoV-2 Spike
RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity
through Increased Human ACE2 Receptor Binding Affinity. J Virol. 2021 Jul
26;95(16):e0061721.

8: Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants
of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit
recombinant vaccines. Braz J Infect Dis. 2021 Aug 17;25(4):101606.

9: Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA.
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand the human
ACE2 receptor on binding affinity and kinetics. Elife. 2021 Aug 26;10:e70658.
10: Tsai MS, Yang YH, Lin YS, Chang GH, Hsu CM, Yeh RA, Shu LH, Cheng YC, Liu
HT, Wu YH, Wu YH, Shen RC, Wu CY. GB-2 blocking the interaction between ACE2 and
wild type and mutation of spike protein of SARS-CoV-2. Biomed Pharmacother. 2021
Aug 5;142:112011.

Products Related to SARS-CoV-2 Spike RBD Beta Variant : SARS-CoV-2